T. Rowe Price Investment Management
TNGX icon

T. Rowe Price Investment Management’s Tango Therapeutics TNGX Stock Holding History

T. Rowe Price Investment Management’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.88M Sell
252,109
-187,906
-43% -$4.65M 0.01% 630
2026
Q1 		$9.21M Sell
440,015
-6,198
-1% -$86.3K 0.01% 540
2025
Q4 		$3.95M Sell
446,213
-3,080,146
-87% -$26.5M ﹤0.01% 585
2025
Q3 		$29.6M Buy
3,526,359
+357,133
+11% +$2.42M 0.02% 461
2025
Q2 		$16.2M Sell
3,169,226
-143,223
-4% -$354K 0.01% 525
2025
Q1 		$4.54M Sell
3,312,449
-33,102
-1% -$81.3K ﹤0.01% 589
2024
Q4 		$10.3M Sell
3,345,551
-1,677,595
-33% -$7.79M 0.01% 551
2024
Q3 		$38.7M Buy
5,023,146
+267,167
+6% +$2.55M 0.02% 442
2024
Q2 		$40.8M Buy
4,755,979
+434,428
+10% +$3.36M 0.03% 420
2024
Q1 		$34.3M Buy
4,321,551
+4,034,857
+1,407% +$43.2M 0.02% 449
2023
Q4 		$2.84M Buy
+286,694
New +$2.49M ﹤0.01% 542

Other funds holding TNGX

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

T. Rowe Price Investment Management's TNGX Position: Q2 2026 in Review

T. Rowe Price Investment Management reduced its Tango Therapeutics (TNGX) stake by 43% in Q2 2026, selling an estimated $4.65M and leaving 252,109 shares worth $7.88M. The position accounts for 0.01% of the portfolio, ranked #630.

T. Rowe Price Investment Management first reported a position in TNGX in Q4 2023 and has held it in 11 quarters since. The position peaked at $40.8M in Q2 2024. 248 funds tracked by Wall St. Rank hold TNGX as of Q2 2026.

  • T. Rowe Price Investment Management held 252,109 shares of Tango Therapeutics worth $7.88M as of Q2 2026.
  • T. Rowe Price Investment Management sold 187,906 Tango Therapeutics shares in Q2 2026, an estimated $4.65M.
  • Tango Therapeutics made up 0.01% of T. Rowe Price Investment Management's portfolio in Q2 2026, its #630 holding.
  • T. Rowe Price Investment Management first reported a position in Tango Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • T. Rowe Price Investment Management's Tango Therapeutics position peaked at $40.8M in Q2 2024.
  • 248 funds tracked by Wall St. Rank held Tango Therapeutics as of Q2 2026.

Based on T. Rowe Price Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.